
the conjugation of various low-molecular-weight nat-
urally occurring toxins, including antibiotics, myco-
toxins, phycotoxins (marine toxins), pesticides, and
other agricultural chemicals, to protein carriers have
been established. Proteins, including bovine serum
albumin (BSA), modified BSA, and keyhole limpet
hemocyanin, are most commonly used. In general, if
the hapten has a reactive group such as a carboxylic
or an amino group, it can be conjugated to the protein
directly via one of the following approaches: water-
soluble carbodiimide method, mixed anhydride
method, condensation method in the presence of
formaldehyde (Mannich reaction), cross-linking
with glutaraldehyde, activated ester method through
the formation of N-hydroxysuccinimide (NHS)
esters, 1,1
0
-carbonylimidazole and m-maleimidoben-
zoyl-N-hydroxysuccinimide ester, and many other in-
novative methods. Derivatization is necessary if no
reactive group is present. Before derivatization or
conjugation, one must select appropriate strategies
to insure that certain portions of the hapten molecule
are exposed. Not only the amount of hapten conju-
gated to the protein molecule is important in deter-
mining the effectiveness of the conjugates as an
immunogen, but also the position of the side chain
in the hapten where conjugation is made, as well as
the space between the hapten and protein molecule
are critical. However, a conjugate containing a large
amount of hapten may not necessarily be a better
immunogen. Antibodies have been obtained from
rabbits immunized with immunogen containing only
2 mol of hapten per mole of carrier protein. The
optimum amount of hapten coupled to a protein
that yields a good immunogen should be experimen-
tally determined, but generally is in the range of 10–
20 mol per mole of protein.
0012 Rapid progress in cloning genes for many proteins/
enzymes/toxins in food and agricultural commodities
has led to another approach for the preparation of
immunogens. By knowing the DNA sequence of a
gene, the amino acid sequence for a specific gene
product in which we are interested could be deduced.
Through structural analysis, the highly immunogenic
fragment in this protein could be identified and
chemically synthesized. These peptides could then be
conjugated to a branched-chain lysine to form a mul-
tiple-chain immunogenic polypeptide for immuniza-
tion. Using this approach, it is possible to generate an
antibody for a protein even before it is purified and
characterized.
Preparation of Antibodies
0013 Two approaches have been used for the production of
antibodies. The classic method involves immuniza-
tion of animals and then obtaining the antibodies
from the sera of the immunized animals. Antibodies
obtained by this approach are polyclonal anti-
bodies (PAbs) because they are derived from different
B lymphocyte clones. In this method, immunogens
are mixed with adjuvant and then injected into
animals, most commonly rabbits, intradermally or
subcutaneously through the thigh or on the back at
multiple sites. For production of a large quantity of
antiserum, large animals such goats and horses are
used. Other animals, such as pigs and mice, have
also been used. Production of antibody has been
optimized by immunization of chickens and then
isolation of antibody from eggs.
0014The amount of immunogen used in the immuniza-
tion varies considerably. In general, 1–2 mg protein is
used for each rabbit. To avoid toxicity of some food-
borne bacterial toxins, a smaller amount of toxins or
toxoids are used in the initial immunization (e.g.,
5 mg) and this is followed by a gradual increase in
dose for subsequent booster injections. For haptens,
200–500 mg of conjugate is generally used in each
injection. Although antiserum obtained from animals
could be used directly in the immunoassay, simple
purification such as ammonium sulfate precipitation
is generally necessary. Further purification of anti-
serum through various chromatographic methods
can improve the efficacy of immunoassays.
0015If the immunogen is highly immunogenic, antibody
titers, as determined by different approaches such
as immunodiffusion, radioimmunoassay (RIA) or
enzyme immunoassay (EIA), usually start to increase
at 4–7 weeks. Subsequent booster injections are gen-
erally performed once a month. Since PAbs are het-
erogeneous, it is advisable that the purified antigen be
used in the titer determination. For haptens, a specific
hapten-marker must be used. Use of inadequate
antigen or hapten-markers usually fails to provide
information regarding whether the immunogen and
immunization protocols are effective.
0016Although production of PAbs is relatively simple
and the affinity of Pabs is generally high, they are
heterogeneous, and their supply is limited. With in-
creasing demand for large amounts of antibodies with
homogeneous properties for immunoassays, as well
as advances in hybridoma technology, specific mono-
clonal antibodies (MAbs) for a number of food com-
ponents and contaminants in foods have also been
produced. In this method, spleen cells obtained from
mice immunized with immunogen or hapten–protein
conjugates are fused with myeloma cells, followed by
propagation of the hybrid cells, and selection and
characterization of the clones, as well as isolation
and characterization of the antibody. Production of
mAbs can either be carried out in tissue culture or in
mice, in which ascites fluids are collected. Thus,
3244 IMMUNOASSAYS/Principles